Atlas Trials

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Clinical trial NCT04526795 · TERMINATED

Trial details

NCT number
NCT04526795
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent T-Cell Prolymphocytic LeukemiaRefractory Acute Biphenotypic LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory T-Cell Prolymphocytic Leukemia
Start date
2021-04-09
Primary completion
2024-11-15
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.